CLAREMORE, OK-Ives Health Company has released a brief summary of the touted Java project.
The project was a landmark AIDS study carried out by Slayton-Beedeen, MD, an immunologist and founder of the product T-Factor. Slayton-Beedeed worked with the World Health Organization (WHO) in Jakarta and Bangkok, testing HIV positive patients of Asian descent with elevated HIV RNA and decreased CD-4 counts. They administered T-Factor and found that new hormonal inhibitors of HIV might initiate profound suppression of HIV replication.
They gave these HIV-positive patients the drug and found 80% experienced documented decreases in HIV RNA and enhanced CD-4 counts within 24 weeks.
T-Factor costs less than $3 per day, in comparison to other HIV drug therapies that cost an estimated $80 daily.
New studies of the product are taking place in the US and in Europe.
For more information about the company or T-Factor, visit www.iveshelath.com.
Long COVID: Urgent Findings, Including Brain Alterations, Call for Renewed Public Health Focus
October 21st 2024New research highlights long COVID’s global impact, cognitive decline, and societal consequences, urging renewed focus on prevention, including vaccination, mask use, and better air quality.
Health Care-Associated Burkholderia multivorans Infections Traced to Contaminated Ice Machines
October 14th 2024Contaminated ice machines caused Burkholderia multivorans infections at hospitals in California and Colorado. Health officials recommend stopping ice machine use during clinical care to prevent further outbreaks.